the objective of this study was to investigate the plasma pharmacokinetic profiles, intratumoral concentration and tissue distribution of arsenic trioxide (ato) by drug-eluting beads (deb)-transcatheter arterial chemoembolization (tace) compared with conventional tace (ctace) in a rabbit liver tumor model.
sixty-four rabbits with vx2 liver tumor were established and randomly assigned to four groups equally. the callispheres microspheres (csm)-ato group received deb-tace treatment using ato-loaded csm; the ctace-ato group received ctace treatment using ato mixed with lipiodol; the csm-normal control (nc) group received deb-tace treatment using blank csm; the tae-lipiodol group received ctace treatment using saline mixed with lipiodol. ato concentration in plasma, tumor and normal tissues, and liver and kidney function indexes were evaluated.
the csm-ato group exhibited lower plasma ato concentrations at 10 minutes and 20 minutes post treatment compared with the ctace-ato group. meanwhile, intratumoral ato concentrations were higher in the csm-ato group compared with the ctace-ato group at 3-,7- and 14-days post treatment. in normal liver tissue, heart and muscle tissues, ato concentrations between the csm-ato and ctace groups were similar at each time point; in kidney and lung tissues, ato concentrations were lower in the csm-ato group at 1-day post treatment while they were similar at 3, 7 and 14 days post treatment. also, liver or kidney function indexes were of no difference at each time point between csm-ato and ctace-ato groups.
administration of ato via deb-tace decreases systemic concentration while increasing intratumoral concentration of ato without increasing liver or kidney toxicity compared with ctace.